Boehringer Ingelheim disputes HRSA's Oct. 4 finding that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.

Boehringer Ingelheim Defends its 340B Contract Pharmacy Policy After HRSA Finds it Is Unlawful

Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.

“Boehringer Ingelheim Pharmaceuticals, Inc. is committed to ensuring that its medicines are accessible and affordable to all patients, including through the 340B program,” BI Senior Vice President, Market Access Chris Marsh said in a statement. “Our carefully tailored contract pharmacy policy is fully compliant with the 340B statute and is intended to help ensure that 340B discounts benefit the patients of covered entities.”

Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report